High-performance liquid chromatography method for the determination of mycophenolic acid and its acyl and phenol glucuronide metabolites in human plasma

Therapeutic Drug Monitoring

Volumn 28, Issue 1, 2006, Pages 116-122

  Patel, Chirag G ^a   Akhlaghi, Fatemeh ^a,b  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b Department of Biomedical and Pharmaceutical Sciences   (United States)

Author keywords

AcMPAG; Assay; Concentration; HPLC UV; MPA; MPAG

Indexed keywords

ACYL GLUCURONIDE; DRUG METABOLITE; METHANOL; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHENOLPHTHALEIN; PHENYL GLUCURONIDE; PHOSPHORIC ACID; UNCLASSIFIED DRUG; GLUCURONIC ACID;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; PRIORITY JOURNAL; SOLID PHASE EXTRACTION; ULTRAVIOLET RADIATION; BLOOD; KIDNEY TRANSPLANTATION; METABOLISM; METHODOLOGY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GLUCURONATES; HUMANS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID;

EID: 33745497852     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000177664.96726.56     Document Type: Article

References (24)

1. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34:429-455.
2. Gabardi S, Tran JL, Clarkson MR. Enteric-coated mycophenolate sodium. Ann Pharmacother. 2003;37:1685-1693.
3. Picard N, Ratanasavanh D, Premaud A, et al. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005;33:139-146.
4. Picard N, Marquet P. In vitro study of mycophenolic acid glucuronidation. Drug Metab Dispos. 2004;32:1524.
5. Bowalgaha K, Miners JO. The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. Br J Clin Pharmacol. 2001;52:605-609.
6. Shipkova M, Wieland E, Schutz E, et al. The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes. Transplant Proc. 2001;33:1080-1081.
7. Wieland E, Shipkova M, Schellhaas U, et al. Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? Clin Biochem. 2000;33:107-113.
8. Jones CE, Taylor PJ, Johnson AG. High-performance liquid chromatography determination of mycophenolic acid and its glucuronide metabolite in human plasma. J Chromatogr B Biomed Sci Appl. 1998;708:229-234.
9. Svensson JO, Brattstrom C, Sawe J. A simple HPLC method for simultaneous determination of mycophenolic acid and mycophenolic acid glucuronide in plasma. Ther Drug Monit. 1999;21:322-324.
10. Hosotsubo H, Takahara S, Kokado Y, et al. Rapid and simultaneous determination of mycophenolic acid and its glucuronide conjugate in human plasma by ion-pair reversed-phase high-performance liquid chromatography using isocratic elution. J Chromatogr B Biomed Sci Appl. 2001;753:315-320.
11. Wiwattanawongsa K, Heinzen EL, Kemp DC, et al. Determination of mycophenolic acid and its phenol glucuronide metabolite in human plasma and urine by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 2001;763:35-45.
12. Teshima D, Otsubo K, Kitagawa N, et al. High-performance liquid chromatographic method for mycophenolic acid and its glucuronide in serum and urine. J Clin Pharm Ther. 2003;28:17-22.
13. Aresta A, Palmisano F, Zambonin CG, et al. Simultaneous determination of free mycophenolic acid and its glucuronide in serum of patients under mycophenolate mofetil therapy by ion-pair reversed-phase liquid chromatography with diode array UV detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;810:197-202.
14. Shipkova M, Schutz E, Armstrong VW, et al. Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit. Clin Chem. 2000;46:365-372.
15. Khoschsorur G, Erwa W. Liquid chromatographic method for simultaneous determination of mycophenolic acid and its phenol- and acylglucuronide metabolites in plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;799:355-360.
16. Patel CG, Mendonza AE, Akhlaghi F, et al. Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;813:287-294.
17. Center for Drug Evaluation and Research, Food and Drug Administration. Bioanalytical Method Validation; Guidance for Industry 2001. Available at http://www.fda.gov/cder/guidance/4252fnl.htm. Accessed April 2005.
18. Thummel KE, Shen DD. Appendix II: Design and optimization of dosage regiments: Pharmacokinetic data. In: Hardman JG, Limbird LE, Goodman Gilman A, eds. The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 2001, pp 1917-2023.
19. Shaw LM, Korecka M, Venkataramanan R, et al. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant. 2003;3:534-542.
20. Wieland E, Shipkova M, Schellhaas U, et al. Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? Clin Biochem. 2000;33:107-113.
21. Kaplan B, Gruber SA, Nallamathou R, et al. Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure. Transplantation. 1998;65:1127-1129.
22. Kaplan B, Meier-Kriesche HU, Friedman G, et al. The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharmacol. 1999;39:715-720.
23. Shipkova M, Armstrong VW, Oellerich M, et al. Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit. 2003;25:1-16.
24. Shipkova M, Beck H, Voland A, et al. Identification of protein targets for mycophenolic acid acyl glucuronide in rat liver and colon tissue. Proteomics. 2004;4:2728-2738.